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Abstract: It has been established that patients with chronic kidney disease (CKD) suffer from frequent cardiovascular 
events. On the other hand, recent studies suggest that renal damage tends to worsen in patients with cardiovascular dis-
eases (CVD). Although the mechanisms for the cardiorenal association are unclear, the presence of arteriosclerotic risk 
factors common to both CVD and CKD is important. In arteriosclerosis, vascular derangement progresses not only in the 
heart but also in the kidney. In addition, heart failure, cardiac catheterization and hesitation of medical treatments due to 
renal dysfunction may explain the progression of renal damage. Therefore, the goal of treatments is a total control of arte-
riosclerotic risk factors. Medication should be selected among agents with protective effects on both heart and kidney. It is 
important to always consider the presence of CKD for the treatment of the cardiovascular disease and strictly control the 
risk factors. 
Key Words: CKD, angiotensin II, aldosterone, ARB, hypertension.  
INTRODUCTION 
  Subgroup analyses of epidemiological surveys and large-
scale clinical studies have shown one after another that the 
presence of chronic kidney disease (CKD) worsens the prog-
nosis of cardiovascular disease (CVD) [1, 2]. Various patho-
physiological mechanisms have already been proposed as 
shown in Fig. (1). However, it is not clear whether there is a 
difference in the aggravation of renal function between pa-
tients with CVD and those without CVD, because there have 
hardly been large-scale clinical trials to prove it. Neverthe-
less, because such evidence has begun to accumulate, in the 
present review article we investigate whether renal failure 
tends to progress when CVD is present, and if so, discuss the 
pathophysiological mechanisms and the most appropriate 
treatment strategy. 
1. RENAL FAILURE IN EPIDEMIOLOGICAL SUR-
VEYS INVOLVING PATIENTS WITH CVD 
  The KEEP study [3] examined independent components 
of CKD as a cardiovascular risk state in patients presenting 
both disorders. Because the patients with CKD tended to die 
of CVD, not of renal insufficiency, this study followed 
37,153 residents of 53 years old on average for a mean pe-
riod of 16 months and examined the relation between CKD 
and CVD. During the follow-up period 7.8% of the patients 
suffered a myocardial infarction or cerebrovascular accident. 
Significant risk factors of CVD were gender male (odds ra-
tio; 1.64), smoking (1.73), diabetes mellitus (1.66), hyperten-
sion (1.77), an estimated glomerular filtration rate (GFR) of 
30-59 mL/min/1.73m
2 (1.37), hemoglobin of less than 12.8 
g/dL (1.45) and microalbuminuria of more than 30 mg/L 
(1.28). In comparison with the control group, the mortality 
increased from 3.02 in patients with only CVD and 1.98 in 
those with only CKD to 3.80 in those with both diseases.  
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Fig. (1). Proposed pathophysiological mechanisms for cardiorenal 
syndrome. DM: diabetes mellitus, RAAS: renin angiotensin alsos-
terone system, SNA: sympathetic nervous activity, ADMA: asym-
metric dimethylarginine.
Thus, it is clear that the presence of both disorders requires 
careful management. 
  In the multi institutional observation study by Levin et al.
[4] 313 patients with CKD with an average creatinine clear-
ance of 36 mL/min were followed for 23 months. In this 
study population 27% of the patients had hypertension, 18% 
had chronic glomerulonephritis, 25% had diabetic nephropa-
thy and 8% had polycystic kidney disease. Moreover, 46% of 
the subjects had CVDs such as myocardial infarction, angina 
pectoris, coronary angioplasty, transient ischemic attack, 
cerebrovascular disorder, peripheral vascular disorder or 
congestive heart failure. The frequency of dialysis was sig-
nificantly higher by 1.58 times in patients who concomi-
tantly had CVD. 
  When both CKD and CVD were present, the two trials 
mentioned above showed that the prognosis was poor, but it 
was not absolutely clear whether CVD was a risk factor for 
the worsening of renal disease. O'Hare et al. [5] measured Progression of Renal Dysfunction  Current Cardiology Reviews, 2008, Vol. 4, No. 3    199
the ankle brachial blood pressure index (ABI) and serum 
creatinine concentration in 13,655 subjects of the Athero-
sclerosis Risk in Communities (ARIC) study. They measured 
serum creatinine level again three years later and examined 
the relation with the baseline ABI in those whose serum 
creatinine had increased by more than 50%. The frequency 
of increased creatinine was significantly greater in patients 
with an ABI < 0.9 by 2.16% (odds ratio 2.5) than in patients 
with an ABI 0.9-0.99 (0.9%) and those with an ABI >1 
(0.48%). These results did not differ after the exclusion of 
patients with either renal insufficiency, diabetes mellitus or 
hypertension. The authors concluded that the presence of 
atherosclerosis was a risk factor for exacerbation of the renal 
disease. 
 Elsayed  et al. [6] monitored renal function for 9.3 years 
on average in subjects from the ARIC study and the Cardio-
vascular Health Study (CHS). The patients with an increased 
serum creatinine concentration (by >0.4 mg/dL to 1.2 mg/dL 
or higher in women, or to 1.4 mg/dL in men) or a decrease of 
the estimated GFR (by > 15 mL/min/1.73m
2 or to < 60 
mL/min/1.73m
2) were considered to show renal failure pro-
gression. The baseline creatinine concentration of 13,826 
subjects was 0.9+/-0.2 mg/dL and the estimated GFR was 
89.8+/-20.1 (SD) mL/min/1.73m
2. Renal failure progressed 
in 3.8% of the subjects according to their creatinine concen-
tration and in 2.3% according to the estimated GFR at the 
end of the follow up. At baseline the patients with CVD ac-
counted for 12.9% of the study population. In patients with 
CVD, the odds ratio for progression of renal failure was sig-
nificantly high at 1.70. The result was similar even when 
patients with a high level of creatinine at baseline were ex-
cluded. Risk factors such as hypertension and diabetes melli-
tus were present more frequently and their mobility periods 
were longer in patients with CVD. Thus, it was plausible that 
renal failure tended to progress independent of the presence 
of CKD when CVD was present. 
2. MECHANISMS OF RENAL DAMAGE IN PA-
TIENTS WITH CVD 
  The potential pathophysiological mechanisms for renal 
damage in CVD are:  
a) Presence of Risk Factors Common to CVD and CKD 
  Patients have many risk factors for the progression of 
CVD that also aggravate renal insufficiency. In the 
Framingham Heart study by Fox et al. [7] 2,585 subjects 43 
years old on average who did not show renal disease were 
followed up for 18.5 years and the factors that influenced the 
new onset of renal disease were analyzed. Patients with CKD 
accounted for 9.4% of the population when CKD was de-
fined as a GFR of < 59.25 mL/min/1.73m
2 in women and < 
64.25 mL/min/1.73m
2 in men determined by the equation of 
MDRD. Age, GFR, BMI, diabetes mellitus, smoking, hyper-
tension and low level of HDL-cholesterol contributed to the 
onset. This suggests that risk factors of CVD closely con-
tribute to the new onset of CKD. Furthermore, the frequency 
of CKD increases as the number of risk factors increases. 
During the ARIC study CKD occurred in 7% of patients with 
metabolic syndrome but without diabetes mellitus, and the 
frequency increased significantly more in patients with 
metabolic syndrome than in those without it. The odds ratio 
was higher in subjects with more risk factors [8]. 
  Smoking, which is an arteriosclerotic risk factor, is also a 
risk for renal failure. Bleyer et al. [9] repeated measurements 
of creatinine concentration more than 3 years apart in 4,142 
patients 65 years of age or older. Of them, 2.8% showed ele-
vation of the creatinine level by more than 0.3 mg/dL. This 
correlated with the number of cigarettes smoked, systolic 
blood pressure and intimal thickening of the internal carotid 
artery. In the MRFIT study smoking was shown to be a risk 
factor of end-stage renal disease [10]. The results suggested 
that the presence of arteriosclerotic risk factors leads to CVD 
and CKD. 
b) Atherosclerotic Development of the Renal Vasculature 
   Tracy et al. [11] reported that the hyalinization of kidney 
arterioles parallels coronary atherosclerotic progress in 25 to 
54-year-old autopsy cases. Kasiske et al. [12] reported simi-
lar autopsy findings. They compared 57 cases with mild sys-
temic arterial sclerosis with 57 cases that had moderate or 
severe sclerosis, and they found that the degree of glomeru-
losclerosis, arterial wall area in the kidney and glomerular 
size were larger in the latter group. Furthermore, the glome-
rular area positively correlated with heart weight and the 
degree of coronary atherosclerosis. 
  The mechanisms involved in renal failure caused by hy-
pertension and diabetes mellitus, but not by hypercholes-
terolemia, have already been reviewed in detail. The deposi-
tion of lipoprotein on glomerular mesangial cells and the 
matrix may be important in disordered lipid metabolism [13]. 
In particular, oxidative LDL-cholesterol activates various 
growth factors and causes proliferation of mesangial cells 
and expansion of the matrix. Furthermore, LDL-cholesterol 
promotes the expression of MCP-1 chemokine and inflam-
mation mediators such as IL-6 and NF-B. Development of 
focal glomerulosclerosis and glomerular hypertrophy is as-
sociated with obesity. However, clinical diagnosis of such 
microvascular renal damage associated with arterial sclerosis 
is difficult. This disorder may account for a substantial part 
of the etiology-unknown end-stage renal failure in elderly 
persons. 
DECLINE OF RENAL PERFUSION IN THE PRES-
ENCE OF HEART FAILURE AND ACTIVATION OF 
NEUROHUMORAL FACTORS 
Fig. (2) shows the treatment course of a 41-year-old man 
with dilated cardiomyopathy and altered renal function. He 
did not respond to pharmacotherapy, and hepatic failure and 
renal insufficiency developed. Finally, a left ventricular as-
sist device (LVAD) had to be implanted. Renal function 
normalized immediately as the cardiac output increased. Al-
though such a case is exceptional, prerenal dysfunction is 
commonly observed even in patients with mild heart failure 
[2]. In case of heart failure and the resulting cardiac output 
decrease, the effective volume of circulating blood is re-
duced, baroreceptors are stimulated and excite the sympa-
thetic nervous activity. Besides, renin secretion from the 
juxtaglomerular apparatus is enhanced due to the fall of renal 
perfusion pressure. Both norepinephrine and angiotensin II 
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strict glomerular mesangial cells decreasing the filtration 
area. Furthermore, angiotensin II increases the filtration frac-
tion due to the constrictive action of efferent arterioles; as a 
result, plasma colloid oncotic pressure in the efferent arteri-
ole rises leading to an increase of Na reabsorption from renal 
tubules. Besides, redistribution of blood flow from the corti-
cal nephron to the juxtamedullary nephron, whose Na reab-
sorption ability is enhanced, results in fluid retention. Angio-
tensin II-induced secretion of aldosterone from adrenal zona 
glomerulosa cells promotes Na reabsorption from cortical 
collecting tubules. Furthermore, the decrease of effective 
intraarterial blood volume stimulates secretion of vaso-
pressin (AVP) and causes water retention. Thus, the renin-
angiotensin system (RAS), sympathetic nervous system and 
AVP are mutually activated in a vicious circle (Fig. (3)). 
  The natriuretic peptide family improves the balance of 
these neurohumoral factors. Atrial natriuretic peptide (ANP) 
and brain natriuretic peptide (BNP) inhibit aggravation of 
heart failure through vasodilatory and natriuretic actions. 
Also, natriuretic peptides antagonize the vasoconstrictor ac-
tion and fluid retention action of RAS, sympathetic nervous 
system and AVP. The secretion of both ANP and BNP in-
creases remarkably in heart failure, but the action is not po-
tent enough to completely reduce edema or improve cardiac 
functions. 
  In heart failure, renal blood flow decreases due to the 
decline of cardiac output, but the GFR remains relatively 
constant. This is because intraglomerular pressure is elevated 
by the activation of RAS and the sympathetic nervous sys-
tem. Because natriuretic peptides constrict efferent arterioles, 
while they dilate the afferent arterioles, GFR is relatively 
constant at this point. Moreover, the elevation of venous 
pressure in heart failure results in an increase of vascular 
resistance in the glomerular efferent side. 
  In the compensated state of heart failure, a constant GFR 
and fluid volume increase result in an increase of cardiac 
output, whereas in the decompensated state they lead to a 
reduced cardiac output and an increase of congestion. If re-
nal hypoperfusion persists, it finally leads to ischemic injury 
of renal tissue. On the other hand, elevation of the intra-
glomerular pressure for a long time may induce an increase 
of proteinuria and glomerulosclerosis in patients who have 
already suffered glomerular damage. Furthermore, expres-
Fig. (2). Time course changes in cardiac and renal functions in pa-
tients with dilated cardiomyopathy after implantation of left ven-
tricular assist device (LVAD). DOA: dopamine, DOB: dobutamine, 
CI: cardiac index, Cr: creatinine, BNP: B-type natriuretic peptide. 
Fig. (3). Compensatory mechanisms for renal dysfunction and volume retention in heart failure. 
HT: hypertension, DM: diabetes mellitus, HL: hyperlipidemia, LVH: left ventricular hypertrophy, CHD: coronary heart disease, CO: cardiac 
output, prs: pressure, BP: blood pressure, SNA: sympathetic nervous activity, RAS: renin angiotensin system, AVP: arginine vasopressin, 
RBF: renal blood flow, GFR: glomerular filtration rate, FF: filtration fraction, : decrease or constriction, : increase or dilatation Progression of Renal Dysfunction  Current Cardiology Reviews, 2008, Vol. 4, No. 3    201
sion of proinflammatory cytokines such as TNF-, IL-1ß or 
IL-6 increases in heart failure, and in fact, their levels are 
elevated in circulating blood. It is possible that cytokines 
contribute to the deterioration of the clinical condition of 
patients with heart failure although anticytokine therapies for 
heart failure have not proved successful so far. Renal vascu-
lar inflammation may occur likewise in heart failure. On the 
other hand, the blood level of asymmetric dimethylarginine 
(ADMA), a potent inhibitor of NO synthase, is increased in 
heart failure [14]. In addition to the above mentioned cytoki-
nes, NO synthase inhibition by ADMA causes endothelial 
damage in the renal vasculature. 
4. POSSIBLE RENAL DAMAGE BY AGENTS USED 
TO TREAT AND DIAGNOSE CVD 
a) Contrast Media-Induced Nephropathy 
  Contrast media is the most important agent involved in 
the progression of renal damage in patients with CVD. Hy-
potension, congestive heart failure, less than 60 mL/min/ 
1.73m
2 of GFR, 75 years old or older, anemia, and diabetes 
mellitus are risk factors for contrast media-induced neph-
ropathy. Most patients with CVD present some of these risk 
factors. Hydration with physiological saline most effectively 
prevents contrast media-induced nephropathy at present [15]. 
In addition, it has been reported that this type of nephropathy 
can be prevented by various methods including hemodialy-
sis, dopamine, ANP, etc, but there is no consensus in this 
regard. The utility of elimination of reactive oxygen species 
by N-acetylcysteine and the dose-dependent efficacy of this 
amino acid were recently reported [16]. Hydration combined 
with the administration of N-acetylcysteine is recommended 
because it does not cause severe side effects. Furthermore, 
concomitant administration of bicarbonate with N-acetylcys-
teine also prevents increases in serum creatinine [17]. 
b) Cholesterol Crystal Emboli 
Fig. (4) shows a photograph of the biopsed skin from a 
68-year-old man [18]. The patient showed progressive renal 
dysfunction and eosinophilia, and ultrasonography revealed 
an important degree of aortic atheromatosis. Cholesterol 
crystal emboli were observed in the arterioles. Cholesterol 
emboli in this case occurred spontaneously. However, it is 
highly likely that cholesterol crystal emboli are easily in-
duced by cardiac catheterization in such cases with systemic 
atherosclerosis. Cholesterol emboli may also be involved in 
renal damage considered to be induced by contrast media. 
Fig. (4). Photograph of the biopsed skin from a patient with choles-
terol emboli. Arrow heads indicate cholesterol crystals. Taken from 
ref. [18]; Matsumura T, Hirata Y, et al. Am J Med Sci 2006; 331: 
280-3.
TREATMENT FOR PATIENTS WITH CAR-
DIORENAL SYNDROME 
a) Renal Failure in Large-Scale Clinical Trials for CVD 
  It was shown in the subgroup analyses of major large-
scale clinical studies such as ALLHAT (hypertension) [19], 
VALIANT (myocardial infarction) [20] and CHARM (heart 
failure) studies [21] that cardiovascular events increased as 
renal function decreased. In the subgroup analysis of the 
ALLHAT study [19] the endpoints were analyzed after sub-
jects were distributed into 3 groups with an estimated GFR 
of less than 60 mL/min/1.73m
2, 60-90 mL/min/1.73m
2 and 
more than 90 mL/min/1.73m
2. The incidence of renal events 
(end-stage renal failure [ESRD] or decrease in estimated 
GFR by more than 50%) was higher as the estimated GFR 
decreased, but there was no difference among three kinds of 
medication groups; namely, diuretics, Ca channel blockers 
and ACE inhibitors. However, cardiovascular events oc-
curred much more frequently than renal events. There was 
no difference in the effect of the medication on the onset of 
CVD in patients with any degree of renal dysfunction. 
Therefore, it is possible that the difference in protective ef-
fects among the medication groups is small for progress of 
renal disease, at least in patients with hypertension. In this 
situation the blood-pressure level attained rather than the 
class of antihypertensive agent is more important to prevent 
cardiovascular events, as previously pointed out. 
b) Inhibitors of the Renin-Angiotensin-Aldosterone Sys-
tem (RAAS)  
  The administration of drugs that protect both the heart 
and kidney is reasonably desirable for patients with car-
diorenal syndrome. Among them, the utility of RAAS inhibi-
tors is easy to understand based on the role of RAAS in the 
pathogenesis of cardiac and renal damage. Aldosterone has 
recently been recognized as a substance that causes wide-
range organ damage to an extent similar to that induced by 
angiotensin II. Actually, it was clearly proved by the RALES 
study [22] that spironolactone, an aldosterone receptor 
blocker, improved the prognosis of patients with heart fail-
ure. Moreover, spironolactone reduced proteinurina in some 
patients with the glomerular disease [23]. It has been re-
cently shown that aldosterone increases the release of reac-
tive oxygen species [24]. Its inhibition may explain at least 
in part the organ protection of the aldosterone antagonist. In 
addition to the blood-pressure lowering effect of ACE inhibi-
tors and ARBs [25], the effect of RAAS inhibitors on glome-
rular microcirculation has been proposed as one of the 
mechanisms of renal protection. In other words, angiotensin 
II raises intraglomerular pressure because it constricts more 
potently efferent than afferent glomerular arterioles, and 
thereby it promotes glomerulosclerosis. It was also shown 
that aldosterone exerted direct vasoconstrictor activity in the 
glomeruli. The effect of aldosterone on efferent arterioles is 
more potent than on afferent ones. However, this action of 
aldosterone is nongenomic [26]. Further studies are required 
to confirm it.  
c) Principles for the Treatment of Cardiorenal Syndrome 
  Treatment should aim at attaining a strict control of the 
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cially, an optimal blood pressure of 120/80 mmHg [27] 
should be aimed, although there is no clear evidence of its 
advantage. A positive correlation between baseline blood 
pressure and renal dysfunction exacerbation rate was found 
in 98,759 residents of Okinawa from 1983 to 2000, at the 
time of their medical check up. The incidence of ESRD was 
significantly elevated even in patients with a blood pressure 
slightly higher than normal (130-140/85-90 mmHg) [28]. In 
the subgroup analysis of the CAMELOT study population 
under treatment with various kinds of antihypertensive medi-
cations [29], the atheromatous plaque volume in the coronary 
arteries was larger in patients with a blood pressure of 
140/90 mmHg or higher, did not change in those with 120-
140/80-90 mmHg and decreased significantly in those with a 
blood pressure below 120/80 mmHg. According to these 
results, the target blood pressure in high-risk patients with 
both cardiac and renal damage should be the optimal one 
rather than just lower than 140/90 mmHg. A strict control of 
risk factors such as lipids, blood glucose or smoking is like-
wise necessary. 
CONCLUSION 
  It has been clarified that the presence of CKD tends to be 
associated with CVD, and vice versa. It is crucial to under-
stand the basic clinical condition of both organs well, and it 
is necessary to pay attention to iatrogenic etiologies. The 
presence of renal damage must always be considered when 
treating patients with CVD, the same as risk factors, which 
should be strictly controlled. 
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